ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 1448 for:    Prediction | Recruiting, Not yet recruiting, Available Studies

OPTImization of the Dose of tacroliMUS by Bayesian Prediction (OPTIMUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03465410
Recruitment Status : Recruiting
First Posted : March 14, 2018
Last Update Posted : March 14, 2018
Sponsor:
Information provided by (Responsible Party):
NURIA LLOBERAS BLANCH, Hospital Universitari de Bellvitge

Brief Summary:
The pharmacokinetics of tacrolimus (TAC) are characterized by high inter- and intra-individual variability with narrow therapeutic range. Currently, the limiting point of Tac drug monitoring is the inability to individualize doses during the first few days after transplantation. Our group developed a population pharmacokinetic model (PPK) identifying CYP3A4 * 22 and CYP3A5 * 3 polymorphisms and hematocrit as explanatory variables of the observed variability in pre-dose (Co) concentrations. According to this model, the proportion of patients that do not reach the therapeutic target is 40

Condition or disease Intervention/treatment Phase
KIDNEY TRANSPLANTATION Drug: Standard dosage of Tacrolimus Drug: Bayesian Prediction Tacrolimus dosage Phase 4

Detailed Description:

The results of the study of genetic polymorphisms performed in renal transplant patients at our hospital demonstrated the influence of CYP3A5 * 3 and CYP3A4 * 22 single nucleotide polymorphism (SNPs) on exposure to Tac. From these results, the first population pharmacokinetic model was developed, which included CYP3A5 * 3 and CYP3A4 * 22 polymorphisms as well as hematocrit as explanatory variables of interindividual variability. Based on our population model and using the simulation tool, the percentage of patients reaching the therapeutic target based on Co values within the range of 6-10 ng / mL was determined after being dosed according to the strategy of Conventional dosage empirically according to Co achieved. The simulation of 50 Co values according to the conventional dosage allowed to determine the proportion of patients reaching the therapeutic target in each case and their confidence interval. 40% of the patients did not reach the therapeutic objective. Based on the clusters of the two polymorphisms, the percentages of patients on or below exposed varied according to whether they were slow or fast metabolizers respectively. Due to this high variability in Tac PK, the individualization of the Tac posology was calculated by calculating the initial dose according to the population model previously developed and adjusting the subsequent doses, as a function of the Tac Co through Bayesian approximations with the inclusion of genotyping and Hematocrit, can contribute greatly to achieve optimal exposure to the drug from the start of treatment in the immediate post-transplant and reduce the variability observed in the Co-achieved; This may be particularly important for patients with a slow and rapid metabolizer profile. All of this may contribute to minimizing adverse effects, ensuring greater efficacy in the target population, reducing the risk of acute rejection, and reducing associated costs.

In the present study we intend to incorporate pharmacogenomics for its application in de novo patients, which will allow us to perform a more individualized therapy for each patient based on the values of target Co and the CYP3A5 * 3 and CYP3 A4 * 22 polymorphisms of the patient since The initiation of immunosuppressive therapy and thus improve efficiency and decrease adverse effects.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A randomized, prospective, multicenter study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: OPTIMIZATION of the Dose of tacroliMUS by Bayesian Prediction in Renal Transplant Patients Including Pharmacogenetic Variables
Actual Study Start Date : March 21, 2017
Estimated Primary Completion Date : March 21, 2019
Estimated Study Completion Date : March 21, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Tacrolimus

Arm Intervention/treatment
Active Comparator: GROUP I Standard adjustment
Standard dosage of Tacrolimus
Drug: Standard dosage of Tacrolimus
Immediate release Tacrolimus (Prograf/Adoport)
Other Name: Tacrolimus

Experimental: GROUP II Bayesian prediction adjustment
Bayesian prediction Tacrolimus dosage
Drug: Bayesian Prediction Tacrolimus dosage
Immediate release Tacrolimus (Prograf/Adoport)
Other Name: Tacrolimus




Primary Outcome Measures :
  1. Tacrolimus plasmatic concentrations measurement [ Time Frame: Day 6, 10, 15, 30, 60 and 90 post transplant ]
    Concentration measured at day 6, 10, 15, 30, 60 and 90 post transplant and after each Tacrolimus dose adjustment


Secondary Outcome Measures :
  1. Time to achieve Tacrolimus therapeutic target levels [ Time Frame: 90 days ]
    Time to achieve Tacrolimus therapeutic target levels within the 90 days post transplant

  2. Number of Tacrolimus dose changes to achieve target levels [ Time Frame: 90 days ]
    Number of Tacrolimus dose changes to achieve target levels



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Kidney transplant recipients, from cadaveric and living donor.
  • Patients that are going to receive immediate release Tacrolimus (Prograf/Adoport) as part of immunosuppressive treatment.
  • Concomitant immunosuppression with Mycophenolate mofetil/Mycophenolic acid and steroids.
  • Induction with Basiliximab is permitted.
  • Subjects able to provide written informed consent.
  • Female subjects of child-bearing potential must have a negative serum pregnancy test and must be practicing an effective, reliable, and medically approved contraceptive regimen during the study.

Exclusion Criteria:

  • Subjects treated with drugs that can potentially interfere with Tacrolimus, especially CYP3A4 inhibitors (telaprevir, boceprevir, ritonavir, ketoconazole, voriconazole, itraconazole, telithromycin or clarithromycin) or CYP3A4 inductors (rifampicin or rifabutine).
  • Subjects that receive induction treatment with Thymoglobulin or rituximab.
  • Subjects participating in another investigational study within 30 days before inclusion.
  • Subjects with hepatopathy.
  • Subject or donor with a history of any malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin .
  • Female subjects who are pregnant or breast feeding.
  • Subjects receiving an ABO incompatible kidney.
  • Subjects have Donor Specific Antibodies.
  • Recipients of an allograft with ischemic cold time > or = 24 hours.
  • Subjects with a history of active hepatitis C virus (HCV-RNA positive) and/or hepatitis B virus (DNA-HBV or HBsAg positive) infection.
  • Subjects with a history of human immunodeficiency virus (HIV-Ab positive) infection.
  • Subjects with psychiatric or physical illness that could interfere with the ability of the subject to participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03465410


Contacts
Contact: Núria Lloberas, PhD 934035806 nlloberas@ub.edu

Locations
Spain
Hospital Universitari de la Vall d'Hebron Recruiting
Barcelona, Spain
Contact: Francesc Moreso, PhD         
Hospital Universitari de Bellvitge Recruiting
L'Hospitalet De Llobregat, Spain
Contact: Núria Lloberas, PhD    0034934035806    nlloberas@ub.edu   
Sponsors and Collaborators
NURIA LLOBERAS BLANCH
Investigators
Principal Investigator: Núria Lloberas, PhD Hospital Universitari de Bellvitge

Responsible Party: NURIA LLOBERAS BLANCH, Principal Investigator, Hospital Universitari de Bellvitge
ClinicalTrials.gov Identifier: NCT03465410     History of Changes
Other Study ID Numbers: OPTIMUS
First Posted: March 14, 2018    Key Record Dates
Last Update Posted: March 14, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Tacrolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action